An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma
NCT05580328 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2022-11-14
Summary
After enrollment, they received photodynamic therapy and sonodynamic therapy for a maximum of 2 times, and the longest treatment time was 6 months.The investigator will judge whether the second photodynamic therapy+ sonodynamic therapy treatment treatment is necessary according to the tolerance and tumor progress of the subject. The second photodynamic therapy+ sonodynamic therapy treatmentwill be carried out at the end of the sixth month. After the treatment period, the patients will be followed up once in the first, third and sixth months respectively, and then every three months. The observation and follow-up were carried out from the first subject after randomization to the end of 24 months after the last case.
The inspection and follow-up evaluation on the 7th day of the treatment period, including vital sign examination, blood routine examination, urine routine examination, blood biochemical examination, electrocardiogram examination, recording the number of times of plastic stent/metal stent drainage/drainage tube replacement, evaluation of physical status scale, evaluation of quality-of-life scale, recording concomitant medication and adverse events.
At the end of the first, third and sixth month, you need to come to the hospital for follow-up evaluation. In the test group, the investigator shall judge whether the second photodynamic therapy is needed at the end of the sixth month according to the tolerance and tumor progression of the subject. Before receiving the next photodynamic therapy, your body and quality of life must be evaluated according to KPS score and quality of life scale Arrange laboratory and relevant examinations. If the second photodynamic therapy is needed, continue to record the concomitant medication and adverse events at this stage.
During the follow-up period, after the longest treatment period of 6 months, a follow-up was conducted every 3 months until the end of 24 months after the last subject was enrolled in the scheme. Your survival, replacement of plastic stent/metal stent/drainage tube, biliary drainage, treatment methods for cholangiocarcinoma and serious adverse events were recorded during the follow-up.
Conditions
Interventions
- DRUG
-
Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy
Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
Sponsors & Collaborators
-
Second Affiliated Hospital of Guangzhou Medical University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-12-01
- Primary Completion
- 2024-10-01
- Completion
- 2024-10-01
More Related Trials
-
Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma
NCT01328223 ·Status: UNKNOWN
-
Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma
NCT01859169 ·Status: SUSPENDED
-
HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC
NCT05866172 ·Status: UNKNOWN ·Phase: PHASE3
-
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
NCT05811481 ·Status: RECRUITING
-
RT+ Anti-PD-1 for Patients With Advanced HCC (RT+PD-1-HCC)
NCT04193696 ·Status: UNKNOWN ·Phase: PHASE2
-
Targeted Internal Radiation Therapy in Advanced HCC Patients.
NCT02724267 ·Status: COMPLETED ·Phase: NA
-
PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety
NCT06991907 ·Status: COMPLETED ·Phase: NA
-
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
NCT03003065 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Sequential RT After Triple Therapy for uHCC
NCT07052448 ·Status: ENROLLING_BY_INVITATION
-
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
NCT04618367 ·Status: COMPLETED ·Phase: NA
-
A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)
NCT00960167 ·Status: UNKNOWN ·Phase: PHASE1
-
Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
NCT03772132 ·Status: UNKNOWN ·Phase: PHASE2
-
Gemcitabine Plus High-Dose 5-Fu/Leucovorin in the Treatment of Advanced or Metastatic Carcinoma of the Biliary Tract
NCT00201305 ·Status: COMPLETED ·Phase: PHASE2
-
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
NCT06261047 ·Status: COMPLETED
-
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients
NCT06583993 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
NCT06999707 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
NCT06040177 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
NCT06708650 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
NCT04962958 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis
NCT05022628 ·Status: UNKNOWN ·Phase: PHASE4
-
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
NCT05660213 ·Status: NOT_YET_RECRUITING
-
Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
NCT06502080 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
NCT05062837 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
NCT03521219 ·Status: UNKNOWN ·Phase: PHASE2
-
Anti-PD-1therapy Combined With Thermal Ablation for Advanced HCC
NCT03939975 ·Status: COMPLETED ·Phase: PHASE2